CRISPR Therapeutics (CRSP) Misses Q1 EPS by 37c
Tweet
Share
E-mail
Get Alerts CRSP Hot Sheet
Join SI Premium – FREE
CRISPR Therapeutics (NASDAQ: CRSP) reported Q1 EPS of ($1.58), $0.37 worse than the analyst estimate of ($1.21). Revenue for the quarter came in at $860 thousand versus the consensus estimate of $7.1 million.
For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Dingdong (DDL) Reports Q2 EPS of RMB0.90
- Antalpha Platform Holding Co. (ANTA) PT Lowered to $7.50 at B.Riley
- Citi raises Autodesk price target to $269, keeps Neutral rating
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
